In:
AIDS Research and Therapy, Springer Science and Business Media LLC, Vol. 17, No. 1 ( 2020-12)
Abstract:
The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) 〈 50 copies/ml and 〈 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL ( 〈 50 or ≥ 50 copies/ml at the start of the regimen). Results We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL 〈 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL 〈 50 copies/ml, 85.7% and 80.0% had VL 〈 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL 〈 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL 〈 50 copies/ml and 69.2% and 68.2% had VL 〈 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure. Conclusions EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.
Type of Medium:
Online Resource
ISSN:
1742-6405
DOI:
10.1186/s12981-020-00302-2
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2020
detail.hit.zdb_id:
2173450-1